Fmr LLC Has $789.01 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Fmr LLC increased its position in Royalty Pharma plc (NASDAQ:RPRX) by 0.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,890,143 shares of the biopharmaceutical company’s stock after buying an additional 3,442 shares during the period. Fmr LLC’s holdings in Royalty Pharma were worth $789,012,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in RPRX. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Royalty Pharma in the 1st quarter valued at about $487,000. California State Teachers Retirement System boosted its stake in Royalty Pharma by 2.1% during the 1st quarter. California State Teachers Retirement System now owns 649,055 shares of the biopharmaceutical company’s stock valued at $19,712,000 after purchasing an additional 13,533 shares during the last quarter. Tidal Investments LLC boosted its stake in Royalty Pharma by 28.2% during the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock valued at $2,740,000 after purchasing an additional 19,834 shares during the last quarter. Atria Investments Inc acquired a new position in Royalty Pharma during the 1st quarter valued at about $1,185,000. Finally, Aurora Investment Counsel boosted its stake in Royalty Pharma by 7.0% during the 1st quarter. Aurora Investment Counsel now owns 43,385 shares of the biopharmaceutical company’s stock valued at $1,318,000 after purchasing an additional 2,827 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Up 1.2 %

NASDAQ:RPRX opened at $26.60 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $15.67 billion, a PE ratio of 13.78, a price-to-earnings-growth ratio of 4.65 and a beta of 0.47. The firm’s 50 day moving average is $27.19 and its 200 day moving average is $27.35. Royalty Pharma plc has a 12 month low of $25.10 and a 12 month high of $31.66.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.16%. Royalty Pharma’s dividend payout ratio (DPR) is presently 43.52%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on RPRX shares. Citigroup cut their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. The Goldman Sachs Group lifted their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.